News >

Adding PD-1 Inhibitor to Dabrafenib/Trametinib May Improve Outcomes in BRAF+ Melanoma

Brandon Scalea
Published: Friday, Jun 28, 2019

Ryan J. Sullivan, MD

Ryan J. Sullivan, MD

The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) is inducing durable responses in patients with BRAF V600-mutant melanoma, said Ryan J. Sullivan, MD, and researchers hope that the addition of anti–PD-1 therapy to the combination will further improve patient outcomes.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication